Financial Position

Total assets increased JPY2,800 million compared with the end of the previous fiscal year.

As for current assets, cash and time deposits rose JPY5,649 million, and trade notes and accounts receivable grew JPY1,208 million. As for fixed assets, investments in securities declined 6,350 million but deferred income taxes rose JPY2,264 million. Within the net asset section, the capital surplus rose 6,548 million, treasury stock increased JPY1,476 million, and unrealized holding gains on securities declined 3,297 million.

Cash flows from operating activities:

Net cash provided by operating activities increased totaled JPY12,849 million. This was mainly due to JPY16,270 million in income before income taxes and minority interests, JPY2,873 million in depreciation and amortization, and JPY6,829 million in income taxes paid.

Cash flows from investing activities:

Net cash used in investing activities totaled JPY1,381 million. This was primarily the result of JPY18,482 million for the purchase of securities, JPY20,303 million from the sale or redemption of short-term securities, 2,208 million for the purchase of tangible fixed assets, and JPY1,630 million for the purchase investment securities.

Cash flow from financing activities:

Net cash used in financing operations totaled JPY4,445 million. This was chiefly the result of JPY1,675 million used for the purchase of treasury stock and JPY2,303 million for the payment of dividends.

Therefore, the term-end balance of cash and cash equivalents increased JPY6,649 million over the previous fiscal period to JPY23,813 million.

Outlook for Fiscal Year Ending March 31, 2010

Fiscal 2010 sales are expected to increase JPY4,307 million (3.4%) year on year to JPY130,000 million. Furthermore, operating income is projected to increase JPY782 million (4.9%) to JPY16,600 million and ordinary income is forecast to increase 1,267 million (8.3%) year on year to 16,600 million. Fiscal 2010 net income is projected to increase JPY447 million (5.0%) year on year to JPY9,300 million.

(1) Consumer Products Operation

As consumers became more hesitant to spend and demanded lower prices, the Group introduced nine new products that meet the potential needs of consumers in order to generate demand through new high-added-value products. These products included the anti-obesity medication Bisuratto Gold, which reduces access body fat by improving the body’s metabolizing of fats, the room deodorizer Shoshu Suikomu, which eliminates odors as air passes through a porous gel, the pleasant-feeling ear brush Tenshi-no-mimigaki, which provides an appropriate level of stimulation to the ear, and the specialized eye glass cleaner Megane-kurina-awa-shanpu, which makes it possible to wash a whole pair of glasses. In addition, the Group will actively work to sell existing brands using marketing plans tailored to each brand and strive to expand overseas market, particularly for the body warmers.

Fiscal 2010 sales are expected to increase JPY3,380 million (3.0%) year on year to JPY116,000 million. Furthermore, operating income is projected to increase JPYmillion (3.1%) to JPY16,400 million.

(2) Medical Devices Operation

Within the Kobayashi Medical Company, aggressive efforts were made to develop the company’s own brand of products while further expanding its lineup of products in fields that the company has already entered such as surgery room related products, respirator products, and orthopedic products. As for eVent Medical Ltd., the company worked to strengthen the sales of artificial respirators through the world, particularly in the U.S.

Fiscal 2010 sales are expected to increase JPY675 million year on year to JPY120,000 million. Furthermore, operating loss is projected to improve JPY454 million to JPY100 million.